Press Release - May 17, 2017
Heidelberg, Germany, May 17, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that data for Affimed’s preclinical AFM24 and AFM26 programs will be presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting being held June 2 – 6, 2017 in Chicago, IL and at the EACR-AACR-SIC Special Conference 2017 being held June 24 – 27, 2017 in Florence, Italy, respectively.
Abstract: AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma (#8045)
Poster: Monday, June 5, 2017 8:00 AM-11:30 AM CST, Session Hematologic Malignancies
AFM24 (abstract only)
Abstract: EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies (#e14001)
Online Publication: Wednesday, May 17, 2017, 5:00 PM EDT
Full abstracts can be accessed on the ASCO website at abstracts.asco.org.
Abstract: AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma
Poster: #575, Monday, June 26, 2017, 10:15 AM-5:00 PM CET, Session "Tumour Immunology II"
Abstract: High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors
Poster: #574, Monday, June 26, 2017, 10:15 AM-5:00 PM CET, Session "Tumour Immunology II"
Abstracts to be released June 23, 2017.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341